ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as â??che… Más…
Springer.com new in stock. Gastos de envío:zzgl. Versandkosten. (EUR 0.00) Details... |
ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemo… Más…
Springer.com new in stock. Gastos de envío:zzgl. Versandkosten., más gastos de envío Details... |
ISBN: 9783642282966
; PDF; Scientific, Technical and Medical > Clinical & internal medicine > Diseases & disorders > Oncology, Gabler Verlag
hive.co.uk No. 9783642282966. Gastos de envío:Instock, Despatched same working day before 3pm, zzgl. Versandkosten., más gastos de envío Details... |
2012, ISBN: 9783642282966
[ED: 1], Auflage, eBook Download (PDF), eBooks, [PU: Springer-Verlag]
lehmanns.de Gastos de envío:Download sofort lieferbar, , Versandkostenfrei innerhalb der BRD (EUR 0.00) Details... |
2012, ISBN: 9783642282966
2012, eBook Download (PDF), eBooks, [PU: Springer Berlin]
lehmanns.de Gastos de envío:Download sofort lieferbar, , Versandkostenfrei innerhalb der BRD. (EUR 0.00) Details... |
ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as â??che… Más…
ISBN: 9783642282966
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemo… Más…
ISBN: 9783642282966
; PDF; Scientific, Technical and Medical > Clinical & internal medicine > Diseases & disorders > Oncology, Gabler Verlag
2012, ISBN: 9783642282966
[ED: 1], Auflage, eBook Download (PDF), eBooks, [PU: Springer-Verlag]
2012, ISBN: 9783642282966
2012, eBook Download (PDF), eBooks, [PU: Springer Berlin]
Datos bibliográficos del mejor libro coincidente
Autor: | |
Título: | |
ISBN: |
Detalles del libro - Therapeutic Kinase Inhibitors
EAN (ISBN-13): 9783642282966
ISBN (ISBN-10): 3642282962
Año de publicación: 2012
Editorial: Springer Berlin
234 Páginas
Idioma: eng/Englisch
Libro en la base de datos desde 2012-12-03T14:22:03-06:00 (Mexico City)
Página de detalles modificada por última vez el 2023-10-25T06:54:19-06:00 (Mexico City)
ISBN/EAN: 9783642282966
ISBN - escritura alterna:
3-642-28296-2, 978-3-642-28296-6
Mode alterno de escritura y términos de búsqueda relacionados:
Autor del libro: sawyer, mell, mellin, melling, grabinski
Título del libro: kina kina
Datos del la editorial
Autor: Ingo K. Mellinghoff; Charles L. Sawyers
Título: Current Topics in Microbiology and Immunology; Therapeutic Kinase Inhibitors
Editorial: Springer; Springer Berlin
234 Páginas
Año de publicación: 2012-11-27
Berlin; Heidelberg; DE
Idioma: Inglés
149,79 € (DE)
154,00 € (AT)
177,00 CHF (CH)
Available
X, 234 p.
EA; E107; eBook; Nonbooks, PBS / Medizin/Nichtklinische Fächer; Onkologie; Verstehen; Mitogen Activated Protein Kinase (MAPK); Raf kinases; biomarkers; chemical library; clinical trial design; drug development; drug efficacy; epigenetics; gastrointestinal stromal tumor (GIST); genetically engineered mouse models (GEMMs); glioblastoma; lung adenocarcinoma; lung cancer; melanoma; myeloproliferative neoplasms; small molecules; B; Cancer Biology; Biomedical and Life Sciences; BB
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.
Includes supplementary material: sn.pub/extras
Más, otros libros, que pueden ser muy parecidos a este:
Último libro similar:
9783642445804 Therapeutic Kinase Inhibitors (Sawyers, Charles L. (Herausgeber); Mellinghoff, Ingo K. (Herausgeber))
< para archivar...